The share price of TH MEDICAL-B (02697) has surged to a new all-time high, continuing its strong momentum after breaking through the HK$500 mark yesterday.

During trading on July 14, the stock price reached an intraday high of HK$533.5, setting another record since its listing, and was last quoted at HK$530, up 10.69%, bringing its total market capitalization close to HK$190 billion.

From its issue price of HK$126.2, the stock has accumulated a gain of approximately 320% in the two weeks since its debut.

The rally follows the recent release of the State Council's "15th Five-Year Plan" for National Health, which explicitly outlines comprehensive, end-to-end support for the development and application of innovative drugs and medical devices.

The policy includes measures to optimize the review and approval processes for innovative drugs and clinically urgent medications, increase support for core technologies, key components, and complete systems in high-end medical devices, promote artificial intelligence to empower the entire pharmaceutical industry chain, and improve medical insurance mechanisms to support the high-quality development of innovative drugs and devices.

The market views this policy as forming a systemic support framework for innovative medical devices, covering aspects from regulatory review and R&D to clinical application and insurance reimbursement.

TH MEDICAL-B, as the company with the highest number of approvals in China for puncture surgical robots, sees its integrated "brain-eye-hand" technology pathway and its product matrix ranging from puncture navigation to microwave ablation as highly aligned with the policy's focus on high-end medical devices and AI integration.

This alignment is further amplified by the fact that China's percutaneous puncture surgical robot market is still in its early growth phase, highlighting the company's scarcity value.